1. Home
  2. IRMD vs PCRX Comparison

IRMD vs PCRX Comparison

Compare IRMD & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo iRadimed Corporation

IRMD

iRadimed Corporation

HOLD

Current Price

$96.26

Market Cap

910.4M

Sector

Health Care

ML Signal

HOLD

Logo Pacira BioSciences Inc.

PCRX

Pacira BioSciences Inc.

HOLD

Current Price

$26.26

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IRMD
PCRX
Founded
1992
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
910.4M
1.0B
IPO Year
2014
2011

Fundamental Metrics

Financial Performance
Metric
IRMD
PCRX
Price
$96.26
$26.26
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
7
Target Price
$72.00
$32.86
AVG Volume (30 Days)
74.4K
723.2K
Earning Date
11-03-2025
11-06-2025
Dividend Yield
0.71%
N/A
EPS Growth
13.00
N/A
EPS
1.65
0.47
Revenue
$80,511,268.00
$716,791,000.00
Revenue This Year
$15.17
$6.24
Revenue Next Year
$10.15
$9.53
P/E Ratio
$58.33
$55.78
Revenue Growth
12.91
3.14
52 Week Low
$47.48
$18.17
52 Week High
$98.44
$27.64

Technical Indicators

Market Signals
Indicator
IRMD
PCRX
Relative Strength Index (RSI) 75.36 72.55
Support Level $94.94 $23.63
Resistance Level $98.44 $24.81
Average True Range (ATR) 2.15 0.93
MACD 0.08 0.25
Stochastic Oscillator 80.50 100.00

Price Performance

Historical Comparison
IRMD
PCRX

About IRMD iRadimed Corporation

iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Share on Social Networks: